HeartMate 3 患者新发主动脉瓣关闭不全的发生情况
该回顾性研究比较了 HeartMate 3 与 HeartMate II 左心室辅助装置植入后新发主动脉瓣关闭不全(AI)的发生情况。共纳入 121 例 HeartMate 3 和 270 例 HeartMate II 患者,术后 1 年内新发 AI 的发生率及严重程度在两组间均无显著差异(P = .68)。
要点
- HeartMate 3 与 HeartMate II 术后 1 年新发 AI 发生率无显著差异。
- 两组新发 AI 的严重程度无显著差异。
- 研究排除了既往主动脉瓣手术或术前超过微量 AI 的患者。
核心结论
- HeartMate 3 与 HeartMate II 患者新发主动脉瓣关闭不全的发生率相当。
- 两种装置患者新发 AI 的严重程度无显著差异。
研究设计与样本
- 最终分析纳入 121 例 HeartMate 3 患者和 270 例 HeartMate II 患者,排除有主动脉瓣手术史、同期主动脉瓣手术或术前超过微量 AI 未处理者。
- 新发 AI 定义为 LVAD 植入后出现超过轻度的 AI,术后 1 个月、6 个月和 1 年行超声心动图随访。
主要发现
- 在考虑死亡和心脏移植的竞争风险后,HeartMate II 与 HeartMate 3 患者术后 1 年内新发 AI 的发生率无显著差异(P = .68)。
- 两组患者术后 1 年内新发 AI 的严重程度无显著差异。
临床怎么用
- 临床中不应预期 HeartMate 3 较 HeartMate II 能显著降低新发 AI 的风险。
- 术后 1 年内应按计划行超声心动图监测新发 AI,两者监测策略可一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: De novo aortic insufficiency (AI) is a common adverse event after continuous-flow left ventricular assist device (LVAD) placement and is associated with morbidity and mortality. This study aims to compare the development of de novo AI between HeartMate 3 (Abbott) and HeartMate II LVAD recipients. METHODS: A retrospective review was conducted of clinical characteristics and serial echocardiograms (1 month, 6 months, and 1 year postimplantation) of HeartMate 3 patients implanted between November 2014 and March 2019 and of HeartMate II patients implanted between April 2004 and December 2015 at Columbia University Irving Medical Center. One hundred twenty-two patients were excluded from analysis for a history of aortic valve surgery, concomitant aortic valve surgery with LVAD implant, or more than trace preoperative AI left untreated. De novo AI was defined as development of more than mild AI after LVAD implant. RESULTS: Included in the study were 121 HeartMate 3 patients and 270 HeartMate II patients. After accounting for competing risks of death and transplantation, there was no significant difference in the development of de novo AI by 1 year postimplantation between HeartMate II and HeartMate 3 patients (P = .68). There was no significant difference in severity of AI developed up to 1 year post-implantation between HeartMate II and HeartMate 3 patients. CONCLUSIONS: Development of de novo AI is comparable between HeartMate 3 and HeartMate II patients. There is no significant difference in severity of AI between HeartMate II and HeartMate 3 patients.
引用
- Malick A, Ning Y, Kurlansky PA, et al. Development of De Novo Aortic Insufficiency in Patients With HeartMate 3. Ann Thorac Surg. 2021. PMID: 34624263. doi:10.1016/j.athoracsur.2021.08.074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。